A5044750580- Forensic Toxicology and Drug Analysis
- Schizophrenia research and treatment
- Opioid Use Disorder Treatment
- Cannabis and Cannabinoid Research
- Neurotransmitter Receptor Influence on Behavior
- Prenatal Substance Exposure Effects
- Mental Health Treatment and Access
- Liver Disease Diagnosis and Treatment
- Pharmaceutical Practices and Patient Outcomes
- Pharmacological Receptor Mechanisms and Effects
- Maternal Mental Health During Pregnancy and Postpartum
- Pharmacovigilance and Adverse Drug Reactions
- Attention Deficit Hyperactivity Disorder
- Pharmaceutical studies and practices
- Pharmacological Effects and Toxicity Studies
- Bipolar Disorder and Treatment
- Psychosomatic Disorders and Their Treatments
- Digital Marketing and Social Media
- Liver Disease and Transplantation
- Treatment of Major Depression
- Poisoning and overdose treatments
- Electrolyte and hormonal disorders
- Child Development and Digital Technology
- Impact of Technology on Adolescents
- Epilepsy research and treatment
Janssen (Belgium)
2025
National Institutes of Health
2003-2019
National Institute on Drug Abuse
1985-2019
Sekisui XenoTech (United States)
2019
Cheng Hsin General Hospital
2019
Fu Jen Catholic University
2017
National Taiwan University
2016
Development Center for Biotechnology
2016
National Taiwan University Hospital
2010-2013
The University of Texas Southwestern Medical Center
2013
Office-based treatment of opiate addiction with a sublingual-tablet formulation buprenorphine and naloxone has been proposed, but its efficacy safety have not well studied.We conducted multicenter, randomized, placebo-controlled trial involving 326 opiate-addicted persons who were assigned to office-based sublingual tablets consisting (16 mg) in combination (4 mg), alone or placebo given daily for four weeks. The primary outcome measures the percentage urine samples negative opiates...
Global smartphone penetration has led to unprecedented addictive behaviors. The aims of this study are develop diagnostic criteria addiction and examine the discriminative ability validity criteria.We developed twelve candidate for characteristic symptoms four functional impairment caused by excessive use. participants consisted 281 college students. Each participant was systematically assessed smartphone-using behaviors psychiatrist's structured interview. sensitivity, specificity, accuracy...
The time course of 11-nor-9-carboxy-Δ9-tetrahydrocannnabinol (THCCOOH) elimination in urine was characterized 60 cannabis users during 24 h monitored abstinence on a closed research unit for up to 30 days. Six thousand, one hundred fifty-eight individual specimens were screened by immunoassay with values ≥ 50 ng/mL classified as positive. Urine confirmed THCCOOH gas chromatography-mass spectrometry following base hydrolysis and liquid-liquid or solid-phase extraction. In 60%, the maximum...
The present study, conducted as part of the development a buprenorphine/naloxone combination product, was designed to evaluate individual and combined effects intravenously administered buprenorphine naloxone. This in-patient trial used randomized, double-blind, crossover design. Ten opioid-dependent male subjects were stabilized maintained on morphine, 15 mg given intramuscularly four times daily. Then, at 48- 72-h intervals, received one following by intravenous injection: (1) placebo, (2)...
To develop and validate empirically a mathematical model for identifying new cannabis use in chronic, daily smokers.
Abstract Background Antipsychotics can potentially induce various involuntary movement, such as extrapyramidal symptoms (EPS) and tardive dyskinesia (TD)1. The specific risk associated with different classes of antipsychotics in causing these side effects the Japanese population remains unclear. Aims & Objectives aim this study is to investigate developing EPS TD relation compared other medications well assess variation across antipsychotics. Method We conducted an analysis cases...
Abstract Background Paliperidone palmitate three-month (PP3M) is a long-acting injectable antipsychotic approved in Japan since November 2020. It indicated for patients with schizophrenia who have been stabilized through at least 4 months of PP1M monotherapy without concomitant use oral antipsychotics. Furthermore, the label discourages continuation PP3M treatment after initiation use. The patient population more limited compared to other counties, and there paucity real-world data on...
Abstract Background Paliperidone palmitate 3-monthly formulation (PP3M) is a long-acting antipsychotic launched in Japan November 2020. The efficacy and safety of PP3M patients with schizophrenia were confirmed the two previous phase III clinical trials (Berwaerts et al., 2015; Savitz 2016). However, data under practice setting limited. Aims & Objectives To evaluate treatment continuation rate settings gain insight into its practical utilization. Method study enrolled from 2020 to 2022...
A biodegradable sustained-release naltrexone bead preparation containing 70% in a physical mixture with copolymer of 90% lactic acid and 10% glycolic was evaluated three male subjects. Each subject received 10-mg iv dose HCl 63-mg by subcutaneous implantation beads. Kinetics estimated from the intravenous indicated plasma clearance range 3.1 to 3.4 l/min t½ 1.7 3.7 hr. After implantation, average levels were maintained at 0.3 0.4 ng/ml naltrexol 1.0 for period approximately 1 mo, during...
In this investigation, the pharmacokinetic and pharmacodynamic properties were determined of multiple doses sublingual tablets containing either buprenorphine alone or naloxone. Subjects experienced opiate users who received escalating (4-24 mg) in combination with Peak concentration (Cmax) area under concentration-time curves (AUCs) increased for both naloxone doses. Significant differences found across range administered dose-adjusted Cmax tablet formulations AUCs buprenorphine-naloxone...
Global smartphone expansion has brought about unprecedented addictive behaviors. The current diagnosis of addiction is based solely on information from clinical interview. This study aimed to incorporate application (app)-recorded data into psychiatric criteria for the and examine predictive ability app-recorded addiction.Smartphone use 79 college students were recorded by a newly developed app 1 month between December 1, 2013, May 31, 2014. For each participant, psychiatrists made 2...
Objective To examine the disparities in psychiatric service utilisation over a 10-year period for patients with first admission psychosis relation to urban–rural residence following implementation of universal health coverage Taiwan. Design Population-based retrospective cohort study. Setting Taiwan's National Health Insurance Research Database, which has population rate 99% and contains all medical claim records nationwide at least one between 1996 2007. Participants 69 690 aged 15–59 years...
Abstract For more than a decade, first responders and the general public have been able to treat suspected opioid overdoses using an improvised nasal naloxone device (INND) constructed from prefilled syringe containing 2 mg of (1 mg/mL) attached mucosal atomization device. In recent years, U.S. Food Drug Administration (FDA)–approved Ezvio, autoinjector that delivers by intramuscular injection Narcan spray (2‐ 4‐mg strengths; 0.1 mL/dose) for emergency treatment known or overdose. The...
Background: Dynamic instability in cardiac repolarization may contribute to drug‐induced arrhythmogenesis. We hypothesized that intravenous cocaine would significantly destabilize as measured by QT variability. Methods and Results: Twenty‐nine cocaine‐experienced volunteers not seeking treatment for addiction received randomized, sequential infusions of placebo or (20 40 mg). Five‐minute epochs digitized ECG were recorded 10 minutes before, during, at intervals following the infusions....
Abstract Based on its high affinity for μ opiate receptors and reported half‐life after oral administration, the pharmacokinetic properties of intranasal naltrexone were examined to evaluate potential treat opioid overdose. This study was prompted by marked rise in overdose deaths linked synthetic opioids like fentanyl, which may require more potent, longer‐lived antagonists than naloxone. Both maximum plasma concentration (C max ) time (T reach C (4 mg) comparable values a Food Drug...
Naloxone (17-allyl-4,5<i>α</i>-epoxy-3,14-dihydroxymorphinan-6-one HCl), a <i>μ</i>-opioid receptor antagonist, is administered intranasally to reverse an opioid overdose but its short half-life may necessitate subsequent doses. The addition of naltrexone [17-(cyclopropylmethyl)-4,5<i>α</i>-epoxy-3,14-dihydroxymorphinan-6-one], another <i>μ</i>-receptor which has reported 3 1/2 hours, extend the available time receive medical treatment. In phase 1 pharmacokinetic study, healthy adults were...